SAN DIEGO – Treating gouty arthritis is problematic in patients who have contraindications for, or are unresponsive or intolerant of, nonsteroidal antiinflammatory drugs (NSAIDs) or colchicine. A new study has found, however, that canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, may be an alternative.
Researchers from the San Diego VAMC and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego in, La Jolla pooled data from two trials — β-RELIEVED and β-RELIEVED II, involving a total of about 500 patients — for a retrospective analysis. The trials collected different responses, including patient-reported outcomes (PRO, according to the report published recently in the International Journal of Clinical Practice.1
Results indicated that, on average, patients receiving CAN met a higher percentage of response criteria (65%) than patients receiving triamcinolone acetonide (TA) (49%) The drug also appeared to produce long term benefits.
“CAN was superior to TA across multiple health-outcome variables comprising clinical markers and PRO over 12 weeks in patients contraindicated, intolerant or unresponsive to NSAIDs and/or colchicine,” the authors wrote.
1 Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ. Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures. Int J Clin Pract. 2014 Oct 9. doi: 10.1111/ijcp.12521. [Epub ahead of print] PubMed PMID: 25298264.
OMAHA, NE—The most common form of inflammatory arthritis—gout—affects about eight million Americans. The disease causes intensely painful flares, but despite the availability of several drugs to manage this chronic, incurable condition, ongoing adherence to therapy... View Article
CHICAGO—The pace of U.S. Food and Drug Administration approval of oral anticancer medications has rapidly increased, from less than one a year at the turn of the century to 10 in 2018. While patients generally... View Article